



Clinical Trial Opportunities

Updated Dec. 7, 2020

For more information on our studies call our research line at **416-386-9606** or email **research@memorydisorders.ca**

Alzheimer's Disease Prevention

AHEAD 3-45 Study (Enrolment to begin in February 2021)

To determine whether BAN2401 can prevent progression to symptomatic AD in cognitively normal individuals at risk for AD based on PET amyloid accumulation performed as part of the screening for this study. Individuals with sub-threshold and elevated levels of amyloid will be enrolled.

Who: 55-80 years old, cognitively well.

Duration: Treatment for 216 weeks.

Mild Cognitive Impairment (MCI)

AgeneBio HOPE4MCI

To evaluate the efficacy and safety of levetiracetam on slowing progression of MCI due to AD.

Who: Individuals 55 to 85 years old with MCI.

Duration: Treatment for up to 78 weeks.

Early AD (Mild Cognitive Impairment and Mild AD Dementia)

Eisai CLARITY

To evaluate the efficacy of BAN2401 in slowing disease progression in early AD.

Who: Individuals 50 to 90 years old with MCI or mild dementia due to AD.

Duration: Double blind treatment for 18 months, Open label treatment for up to 2 years.

Eli Lilly TRAILBLAZER-ALZ 2

To evaluate efficacy and safety of donanemab in individuals with early AD.

Who: Individuals 60 to 85 years old with MCI or mild dementia due to AD.

Duration: Treatment for up to 76 weeks.

Anavex 2-73

To evaluate the efficacy and safety of ANAVEX2-73 in individuals with Early AD.

Who: Individuals 60 to 85 years old with MCI or mild dementia due to AD.

Duration: Treatment for up to 48 weeks.

Janssen anti-tau antibody

To evaluate the efficacy and safety of JNJ-63733657 in individuals with early AD.

Who: Individuals 55 to 80 years old with MCI or mild dementia due to AD.

Duration: Treatment for up to 4.5 years.

Alector (Enrolment to begin in January 2021)

To assess the safety, tolerability, and efficacy of AL002 in subjects with early Alzheimer's disease.

Who: Individuals 50 to 85 years old with MCI or mild dementia due to AD.

Duration: Treatment for up to 96 weeks.

Mild to Moderate Alzheimer's Dementia

Green Memory (Enrolment to begin in January 2021)

To evaluate the efficacy of oligomannate (GV-971) in treatment of mild to moderate AD.

Who: Individuals 50 to 85 years old with mild to moderate dementia due to AD.

Duration: Treatment for up to 52 weeks. Participants who completes the 52 weeks of treatment may continue into a 26 week Open Label Extension (if eligible).

Cassava (Enrolment to begin in February 2021)

To assess the safety, tolerability and efficacy of simufilam (PTI-125) in subjects with mild to moderate Alzheimer's disease.

Who: Individuals 50 to 85 years old with mild to moderate dementia due to AD.

Duration: Treatment up to 12 months.

Moderate to Severe Alzheimer's disease

Vielight

To evaluate the feasibility, safety, and efficacy of Vielight Neuro RX Gamma for the treatment of moderate to severe AD.

Who: Individuals 50+ with moderate to severe Alzheimer's disease.

Duration: Treatment for up to 12 weeks.

Non-Interventional Studies

RetiSpec

RetiSpec is a medical imaging company developing a tool for the early detection of Alzheimer's disease biomarkers in the eye.

Who: Individuals 50-90 who are at risk for or those who have pre-clinical Alzheimer's disease or who meet the clinical criteria for MCI and individuals 50-90 who are cognitively normal

Duration: A two hour session involving photos of the eye using standard eye exam equipment.

For more information on our studies call our research line at **416-386-9606** or email **research@memorydisorders.ca**